SynAct Pharma AB (FRA:8F8)
Germany · Delayed Price · Currency is EUR 1.892
-0.010 (-0.53%)
Last updated: Nov 28, 2025, 3:29 PM CET
SynAct Pharma AB Statistics
Total Valuation
FRA:8F8 has a market cap or net worth of EUR 103.00 million. The enterprise value is 96.02 million.
| Market Cap | 103.00M |
| Enterprise Value | 96.02M |
Important Dates
The next estimated earnings date is Wednesday, February 18, 2026.
| Earnings Date | Feb 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 53.33M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +27.46% |
| Shares Change (QoQ) | +7.93% |
| Owned by Insiders (%) | 7.93% |
| Owned by Institutions (%) | 15.92% |
| Float | 32.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 78.78 |
| PS Ratio | n/a |
| PB Ratio | 5.84 |
| P/TBV Ratio | 5.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.99 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.28 |
| Quick Ratio | 3.18 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -64.76 |
Financial Efficiency
Return on equity (ROE) is -58.39% and return on invested capital (ROIC) is -38.95%.
| Return on Equity (ROE) | -58.39% |
| Return on Assets (ROA) | -30.35% |
| Return on Invested Capital (ROIC) | -38.95% |
| Return on Capital Employed (ROCE) | -51.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.20M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -916,448 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +124.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +124.57% |
| 50-Day Moving Average | 1.94 |
| 200-Day Moving Average | 1.70 |
| Relative Strength Index (RSI) | 50.13 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.34M |
| Pretax Income | -10.53M |
| Net Income | -9.61M |
| EBITDA | n/a |
| EBIT | -10.34M |
| Earnings Per Share (EPS) | -0.20 |
Balance Sheet
The company has 7.05 million in cash and 125,365 in debt, giving a net cash position of 6.92 million.
| Cash & Cash Equivalents | 7.05M |
| Total Debt | 125,365 |
| Net Cash | 6.92M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 17.62M |
| Book Value Per Share | 0.33 |
| Working Capital | 6.42M |
Cash Flow
| Operating Cash Flow | -8.24M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:8F8 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.46% |
| Shareholder Yield | -27.46% |
| Earnings Yield | -9.33% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |